Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Receivables (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Receivables data on record, last reported at $21.4 million in Q4 2025.

  • On a quarterly basis, Receivables rose 3.36% to $21.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.4 million, a 3.36% increase, with the full-year FY2025 number at $21.4 million, up 3.36% from a year prior.
  • Receivables reached $21.4 million in Q4 2025 per PCVX's latest filing, up from $400000.0 in the prior quarter.
  • Over the last five years, Receivables for PCVX hit a ceiling of $21.4 million in Q4 2025 and a floor of $100000.0 in Q1 2022.
  • A 5-year average of $5.7 million and a median of $3.0 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 662.57% in 2023, then plummeted 98.82% in 2025.
  • Tracing PCVX's Receivables over 5 years: stood at $1.2 million in 2021, then skyrocketed by 220.67% to $3.8 million in 2022, then fell by 6.5% to $3.6 million in 2023, then skyrocketed by 474.26% to $20.7 million in 2024, then rose by 3.36% to $21.4 million in 2025.
  • Business Quant data shows Receivables for PCVX at $21.4 million in Q4 2025, $400000.0 in Q3 2025, and $100000.0 in Q2 2025.